The European Medicines Agency said on Thursday it was investigating Swiss group Roche Holding AG after a routine inspection found it had failed to properly assess 80,000 cases of possible adverse drug reactions. The issue relates to medicines from across the Roche product range that were part of a financial reimbursement system in the United States. Roche is the world’s largest maker of cancer medicines and it also produces drugs for viral infections, central nervous system disorders and inflammatory diseases.
